DB Fitzpatrick & Co Inc Boosts Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

DB Fitzpatrick & Co Inc raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.6% in the 4th quarter, Holdings Channel reports. The institutional investor owned 3,608 shares of the medical research company’s stock after buying an additional 256 shares during the period. Thermo Fisher Scientific accounts for approximately 1.7% of DB Fitzpatrick & Co Inc’s investment portfolio, making the stock its 11th largest position. DB Fitzpatrick & Co Inc’s holdings in Thermo Fisher Scientific were worth $1,877,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of TMO. Seven Eight Capital LP raised its position in shares of Thermo Fisher Scientific by 29.4% during the 2nd quarter. Seven Eight Capital LP now owns 2,586 shares of the medical research company’s stock valued at $1,430,000 after buying an additional 588 shares during the period. Intech Investment Management LLC raised its position in Thermo Fisher Scientific by 19.4% in the second quarter. Intech Investment Management LLC now owns 3,142 shares of the medical research company’s stock valued at $1,738,000 after purchasing an additional 510 shares during the period. Brighton Jones LLC grew its holdings in shares of Thermo Fisher Scientific by 5.9% during the 2nd quarter. Brighton Jones LLC now owns 4,297 shares of the medical research company’s stock worth $2,376,000 after purchasing an additional 240 shares during the period. Ieq Capital LLC increased its position in shares of Thermo Fisher Scientific by 7.5% during the 2nd quarter. Ieq Capital LLC now owns 38,209 shares of the medical research company’s stock worth $21,130,000 after purchasing an additional 2,667 shares during the last quarter. Finally, GM Advisory Group LLC boosted its stake in Thermo Fisher Scientific by 2.0% during the second quarter. GM Advisory Group LLC now owns 1,949 shares of the medical research company’s stock worth $1,078,000 after buying an additional 38 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the completion of the sale, the senior vice president now directly owns 12,736 shares of the company’s stock, valued at approximately $7,134,197.76. This represents a 13.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $530.26, for a total value of $5,302,600.00. Following the transaction, the chief executive officer now directly owns 111,192 shares in the company, valued at approximately $58,960,669.92. This represents a 8.25 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 47,150 shares of company stock worth $25,954,465 in the last 90 days. 0.34% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Evercore ISI decreased their price objective on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Wells Fargo & Company lowered their price target on Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Morgan Stanley decreased their target price on Thermo Fisher Scientific from $670.00 to $647.00 and set an “overweight” rating on the stock in a research note on Monday, January 13th. Sanford C. Bernstein raised Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price for the company in a research report on Friday, January 10th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research note on Friday, September 20th. Four research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $648.95.

Thermo Fisher Scientific Stock Down 0.4 %

Shares of NYSE:TMO opened at $559.72 on Friday. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The firm has a 50 day simple moving average of $529.80 and a 200-day simple moving average of $567.97. The company has a market capitalization of $214.09 billion, a PE ratio of 35.09, a P/E/G ratio of 3.59 and a beta of 0.76. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.03. The company had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business’s quarterly revenue was up .2% compared to the same quarter last year. During the same quarter last year, the company posted $5.69 earnings per share. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has approved a share buyback program on Friday, November 15th that permits the company to buyback $4.00 billion in shares. This buyback authorization permits the medical research company to buy up to 2% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.